1-12 of 12
James Spicer
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase Ib Study of the Immunocytokine Simlukafusp Alfa (FAP-IL2v) in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma

Aaron R. Hansen, Carlos A. Gomez-Roca, Debbie G. J. Robbrecht, Loic Verlingue, Antoine Italiano, Julie E. Bauman, Neeltje Steeghs, Hans Prenen, Jérôme Fayette, James Spicer, Jiaxin Niu, Christin Habigt, Meike Schneider, Stefan Evers, Nassim Sleiman, David Dejardin, Caroline Ardeshir, Daniela Schmid, Christophe Boetsch, Jehad Charo, Anton Kraxner, Volker Teichgräber, Nino Keshelava, Marcelo R. Bonomi
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (24): 5540–5547.
https://doi.org/10.1158/1078-0432.CCR-24-1562
Published: 16 December 2024
View article titled, Phase Ib Study of the Immunocytokine Simlukafusp Alfa (FAP-IL2v) in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma
Open the PDF for Phase Ib Study of the Immunocytokine Simlukafusp Alfa (FAP-IL2v) in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Safety, Antitumor Activity, and T-cell Responses in a Dose-Ranging Phase I Trial of the Oncolytic Peptide LTX-315 in Patients with Solid Tumors

James Spicer, Aurélien Marabelle, Jean-Francois Baurain, Nina Louise Jebsen, Dag Erik Jøssang, Ahmad Awada, Rebecca Kristeleit, Delphine Loirat, George Lazaridis, Christiane Jungels, Paal Brunsvig, Berit Nicolaisen, Andrew Saunders, Hamina Patel, Jérôme Galon, Fabienne Hermitte, Ketil André Camilio, Brynjar Mauseth, Vibeke Sundvold, Baldur Sveinbjørnsson, Øystein Rekdal
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (10): 2755–2763.
https://doi.org/10.1158/1078-0432.CCR-20-3435
Published: 15 May 2021
View article titled, Safety, Antitumor Activity, and T-cell Responses in a Dose-Ranging Phase I Trial of the Oncolytic Peptide LTX-315 in Patients with Solid Tumors
Open the PDF for Safety, Antitumor Activity, and T-cell Responses in a Dose-Ranging Phase I Trial of the Oncolytic Peptide LTX-315 in Patients with Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Abstract S12-03: Clinical and demographic characteristics associated with shorter time to COVID-19 death

Maria J. Monroy-Iglesias, Beth Russell, Charlotte Moss, Gincy George, Kieran Palmer, Sophie Papa, Sheeba Irshad, Paul Ross, James Spicer, Sharam Kordasti, Danielle Crawley, Harriet Wylie, Fidelma Cahill, Anna Haire, Rushan Sylva, Kamarul Zaki, Fareen Rahman, Ailsa Sita-Lumsden, Debra Josephs, Deborah Enting, Mary Lei, Sharmistha Ghosh, Claire Harrison, Angela Swampillai, Elinor Sawyer, Andrea D'Souza, Simon Gomberg, Paul Fields, David Wrench, Kavita Raj, Mary Gleeson, Kate Bailey, Richard Dillon, Matthew Streetly, Austin Kulasekararaj, Thinzar Ko Ko, Vallari Shah, Anne Rigg, Richard Sullivan, Mieke Van Hemelrijck, Saoirse Dolly
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (6_Supplement): S12-03.
https://doi.org/10.1158/1557-3265.COVID-19-21-S12-03
Published: 15 March 2021
View article titled, Abstract S12-03: Clinical and demographic characteristics associated with shorter time to COVID-19 death
Journal Articles

Abstract S09-03: Factors affecting COVID-19 outcomes in cancer patients: A first report from Guy’s Cancer Centre in London

Beth Russell, Charlotte Moss, Sophie Papa, Sheeba Irshad, Paul Ross, James Spicer, Shahram Kordasti, Danielle Crawley, Harriet Wylie, Fidelma Cahill, Anna Haire, Kamarul Zaki, Fareen Rahman, Ailsa Sita-Lumsden, Debra Josephs, Deborah Enting, Mary Lei, Sharmista Ghosh, Claire Harrison, Angela Swampillai, Richard Sullivan, Anne Rigg, Saoirse Dolly, Mieke Van Hemelrijck, Guy's Cancer Real World Evidence Programme
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (18_Supplement): S09-03.
https://doi.org/10.1158/1557-3265.COVID-19-S09-03
Published: 15 September 2020
View article titled, Abstract S09-03: Factors affecting COVID-19 outcomes in cancer patients: A first report from Guy’s Cancer Centre in London
Journal Articles

MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial

Debashis Sarker, Ruth Plummer, Tim Meyer, Mikael H. Sodergren, Bristi Basu, Cheng Ean Chee, Kai-Wen Huang, Daniel H. Palmer, Yuk Ting Ma, T.R. Jeff Evans, Duncan R.C. Spalding, Madhava Pai, Rohini Sharma, David J. Pinato, James Spicer, Sarah Hunter, Vineet Kwatra, Joanna P. Nicholls, David Collin, Robert Nutbrown, Helen Glenny, Sonia Fairbairn, Vikash Reebye, Jon Voutila, Stephanie Dorman, Pinelopi Andrikakou, Peter Lloyd, Steve Felstead, Jenni Vasara, Robert Habib, Chris Wood, Pal Saetrom, Hans E. Huber, David C. Blakey, John J. Rossi, Nagy Habib
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (15): 3936–3946.
https://doi.org/10.1158/1078-0432.CCR-20-0414
Published: 03 August 2020
View article titled, MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial
Open the PDF for MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial in another window
Includes: Supplementary data
Journal Articles

First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer

Geoffrey I. Shapiro, Katherine M. Bell-McGuinn, Julian R. Molina, Johanna Bendell, James Spicer, Eunice L. Kwak, Susan S. Pandya, Robert Millham, Gary Borzillo, Kristen J. Pierce, Lixin Han, Brett E. Houk, Jorge D. Gallo, Maria Alsina, Irene Braña, Josep Tabernero
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2015) 21 (8): 1888–1895.
https://doi.org/10.1158/1078-0432.CCR-14-1306
Published: 14 April 2015
View article titled, First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer
Open the PDF for First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer in another window
Includes: Supplementary data
Journal Articles

Phase I Trial of Cyclophosphamide as an Immune Modulator for Optimizing Oncolytic Reovirus Delivery to Solid Tumors

Victoria Roulstone, Khurum Khan, Hardev S. Pandha, Sarah Rudman, Matt Coffey, George M. Gill, Alan A. Melcher, Richard Vile, Kevin J. Harrington, Johann de Bono, James Spicer
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (6): 1305–1312.
https://doi.org/10.1158/1078-0432.CCR-14-1770
Published: 12 March 2015
View article titled, Phase I Trial of Cyclophosphamide as an Immune Modulator for Optimizing Oncolytic Reovirus Delivery to Solid Tumors
Open the PDF for Phase I Trial of Cyclophosphamide as an Immune Modulator for Optimizing Oncolytic Reovirus Delivery to Solid Tumors in another window
Includes: Supplementary data
Journal Articles

First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer

Sarah Blagden, Aurelius Olmin, Debra Josephs, Chara Stavraka, Andrea Zivi, David J. Pinato, Alan Anthoney, Shaun Decordova, Karen Swales, Ruth Riisnaes, Lorna Pope, Kohei Noguchi, Rie Shiokawa, Michiyasu Inatani, Jenny Prince, Keith Jones, Chris Twelves, James Spicer, Udai Banerji
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (23): 5908–5917.
https://doi.org/10.1158/1078-0432.CCR-14-1315
Published: 30 November 2014
View article titled, First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer
Open the PDF for First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer in another window
Includes: Supplementary data
Journal Articles

First-in-Human Phase I Trial of Two Schedules of OSI-930, a Novel Multikinase Inhibitor, Incorporating Translational Proof-of-Mechanism Studies

Timothy A. Yap, Hendrik-Tobias Arkenau, D. Ross Camidge, Suzanne George, Natalie J. Serkova, Stephen J. Gwyther, Jennifer L. Spratlin, Rohit Lal, James Spicer, Nandita M. Desouza, Martin O. Leach, Jon Chick, Srinivasu Poondru, Ramesh Boinpally, Richard Gedrich, Katie Brock, Andrew Stephens, S. Gail Eckhardt, Stan B. Kaye, George Demetri, Michelle Scurr
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (4): 909–919.
https://doi.org/10.1158/1078-0432.CCR-12-2258
Published: 14 February 2013
View article titled, First-in-Human Phase I Trial of Two Schedules of OSI-930, a Novel Multikinase Inhibitor, Incorporating Translational Proof-of-Mechanism Studies
Open the PDF for First-in-Human Phase I Trial of Two Schedules of OSI-930, a Novel Multikinase Inhibitor, Incorporating Translational Proof-of-Mechanism Studies in another window
Includes: Supplementary data
Journal Articles

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in the Treatment of Epidermal Growth Factor Receptor–Mutant Non–Small Cell Lung Cancer Metastatic to the Brain

Mariam Jamal-Hanjani, James Spicer
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (4): 938–944.
https://doi.org/10.1158/1078-0432.CCR-11-2529
Published: 14 February 2012
View article titled, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in the Treatment of Epidermal Growth Factor Receptor<em>–</em>Mutant Non–Small Cell Lung Cancer Metastatic to the Brain
Open the PDF for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in the Treatment of Epidermal Growth Factor Receptor<em>–</em>Mutant Non–Small Cell Lung Cancer Metastatic to the Brain in another window
Journal Articles

REO-10: A Phase I Study of Intravenous Reovirus and Docetaxel in Patients with Advanced Cancer

Charles Comins, James Spicer, Andrew Protheroe, Victoria Roulstone, Katie Twigger, Christine M. White, Richard Vile, Alan Melcher, Matt C. Coffey, Karl L. Mettinger, Gerard Nuovo, David E. Cohn, Mitch Phelps, Kevin J. Harrington, Hardev S. Pandha
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (22): 5564–5572.
https://doi.org/10.1158/1078-0432.CCR-10-1233
Published: 14 November 2010
View article titled, REO-10: A Phase I Study of Intravenous Reovirus and Docetaxel in Patients with Advanced Cancer
Open the PDF for REO-10: A Phase I Study of Intravenous Reovirus and Docetaxel in Patients with Advanced Cancer in another window
Journal Articles

A First-in-Man Phase I and Pharmacokinetic Study on CHR-2797 (Tosedostat), an Inhibitor of M1 Aminopeptidases, in Patients with Advanced Solid Tumors

Alison H.M. Reid, Andrew Protheroe, Gerhardt Attard, Nikki Hayward, Laura Vidal, James Spicer, Heather M. Shaw, Elizabeth A. Bone, Joanne Carter, Leon Hooftman, Adrian Harris, Johann S. De Bono
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (15): 4978–4985.
https://doi.org/10.1158/1078-0432.CCR-09-0306
Published: 29 July 2009
View article titled, A First-in-Man Phase I and Pharmacokinetic Study on CHR-2797 (Tosedostat), an Inhibitor of M1 Aminopeptidases, in Patients with Advanced Solid Tumors
Open the PDF for A First-in-Man Phase I and Pharmacokinetic Study on CHR-2797 (Tosedostat), an Inhibitor of M1 Aminopeptidases, in Patients with Advanced Solid Tumors in another window